AlphAIAlphAI — Financial news for AI agents
investing.comSEP 171 min read$CELC

Why is Celcuity stock climbing today?

Celcuity (CELC) stock rose 2.9% pre-market after JPMorgan initiated coverage with an Overweight rating and $157 price target, citing Revtorpyk's commercial potential. JPMorgan's revenue estimates are conservative. Other analysts have higher targets. The FDA supplemental NDA submission could expand Revtorpyk's market. The broader market is up, boosting growth and healthcare names.

Original reporting
investing.com
Published Sep 17, 2026, 1:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 1:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$CELC
Bullish
high confidence
Mentioned
$CELC
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CELCBullishHigh
01

Why it matters

The initiation note adds a high‑visibility endorsement, likely attracting institutional buying.

02

Market read

A fresh analyst rating on a small‑cap biotech drives a near‑term price rally and may influence peer valuations.

03

What to watch

Potential competition from other PI3K inhibitors and the modest size of the current addressable market.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

JPMorgan joined existing bullish analysts covering Celcuity, citing commercial potential of Revtorpyk in HR+/HER2‑ breast cancer.

Company-level read

Ticker impact

$CELCBullishHigh confidence
Context

Celcuity stock rose 2.9% in pre‑open trading after JPMorgan initiated coverage with an Overweight rating and a $157 price target.

Expected impact

Expect further short‑term upside as investors digest the rating; target range $150‑$165 in the next 2‑4 weeks.

Evidence & confidence

Analyst initiation is a primary catalyst; the stock already moved 3% on the news, indicating market receptivity.

Market effects

Sector

Boosts sentiment for biotech and oncology‑focused small caps.

Regional

Positive for U.S. Nasdaq‑listed biotech firms.

Global

Limited to investors tracking U.S. biotech sector.

Counterpoint

What could challenge this read

The drug's label expansion is still pending FDA approval, which could delay revenue upside.

Key entities

  • Analyst
    JPMorgan

    Initiated coverage with Overweight rating and $157 price target.

  • Company
    Celcuity Inc.

    Biotech developing Revtorpyk for breast cancer.

Read at source← All news

Related articles

SEP 1
$CELCHighAI 8/10

How Investors May Respond To Celcuity (CELC) sNDA For REVTORPYK In PIK3CA-Mutant Breast Cancer

Celcuity Inc. (CELC) submitted an sNDA for REVTORPYK (gedatolisib) to treat HR+/HER2- advanced breast cancer with PIK3CA mutations, based on positive Phase 3 trial data. If approved, it would be the first therapy targeting all class I PI3K isoforms and both mTOR complexes. The company projects $817.9M revenue and $267.5M earnings by 2029, up from current losses. The sNDA builds on the July 2026 approval for non-mutant cases, potentially expanding market reach.

simplywall.st2 min
AUG 30
$CELCMedAI 8/10

What Could Celcuity (CELC) Gain If The FDA Clears REVTORPYK For Breast Cancer?

Celcuity (CELC) submitted a supplemental New Drug Application to the FDA for REVTORPYK to treat advanced breast cancer with PIK3CA mutations. The filing is supported by Phase 3 trial results showing improved progression-free survival. If approved, REVTORPYK could become the first therapy for this indication, potentially expanding Celcuity's market. Management estimates a US$5b to US$6b addressable market and potential peak revenue of US$2.5b to US$3b for gedatolisib in this setting.

simplywall.st2 min
AUG 26
$CELCMedAI 8/10

Celcuity Submits SNDA To FDA For REVTORPYK In Advanced Breast Cancer

Celcuity Inc. (CELC) submitted a supplemental New Drug Application to the FDA for REVTORPYK, an investigational therapy for advanced breast cancer with a PIK3CA mutation. The application is supported by Phase 3 trial data showing significant improvements in progression-free survival and response rates. If approved, REVTORPYK would be the first therapy of its kind for this patient population. CELC stock closed at $92.27, up 1.63%.

rttnews.com1 min
AUG 24
$CELCLow

How Investors May Respond To Celcuity (CELC) Deepening Losses As Gedatolisib Commercial Plans Advance

Celcuity Inc. (CELC) reported a net loss of $78.86 million in Q2 2026, with first-half losses widening to $131.71 million. The company is advancing gedatolisib and preparing for commercialization, with FDA approval of REVTORPYK in July. Investors focus on whether REVTORPYK revenue can offset increased cash burn. Celcuity projects $817.9 million revenue and $267.5 million earnings by 2029, implying a 77% upside from current prices.

simplywall.st3 min
AUG 20
$CELCMed

Celcuity (CELC) Q2 2026 Earnings Call Transcript

Celcuity (CELC) reported Q2 2026 net loss of $78.9M ($1.44/ share), up from $45.3M last year. Cash reserves total $754M, with $557.2M raised from a convertible note offering. The company launched Revtopik, a drug for advanced breast cancer, and plans a supplemental New Drug Application. Clinical trials showed significant reduction in disease progression risk. Management expects cash to fund operations into 2029.

fool.com3 min